No intervention

Pre-clinicalCompleted

1 views this week 0 watching💤 Quiet

Interest: 26/100

Hype Score

Development Stage

Pre-clinical

Phase 1

Phase 2

Phase 3

Approved

Indication / Disease

Optic Neuropathy, Ischemic

Conditions

Optic Neuropathy, Ischemic

Trial Timeline

Nov 1, 2008 → Oct 1, 2012

NCT ID

NCT00759174

About No intervention

No intervention is a pre-clinical stage product being developed by Pfizer for Optic Neuropathy, Ischemic. The current trial status is completed. This product is registered under clinical trial identifier NCT00759174. Target conditions include Optic Neuropathy, Ischemic.

What happened to similar drugs?

4 of 14 similar drugs in Optic Neuropathy, Ischemic were approved

Approved (4) Terminated (4) Active (8)

✅Satralizumab 120 mgChugai PharmaceuticalApproved

🔄Satralizumab + Placebo + Baseline TreatmentChugai PharmaceuticalPhase 3

🔄Satralizumab + PlaceboChugai PharmaceuticalPhase 3

🔄satralizumab + azathioprine (AZA) + mycophenolate mofetil (MMF) + oral corticosteroidsRochePhase 3

🔄SatralizumabRochePhase 3

✅InebilizumabAmgenApproved

❌Zyvox - linezolid + Matched controlPfizerPhase 3

Hype Score Breakdown

Clinical

Activity

Company

Novelty

Community

Clinical Trials (1)

NCT ID	Phase	Status	Start	Completion	Indication
NCT00759174	Pre-clinical	Completed	Nov 1, 2008	Oct 1, 2012	Optic Neuropathy, Ischemic

Competing Products

20 competing products in Optic Neuropathy, Ischemic

See all competitors

Product	Company	Stage	Hype Score
Satralizumab 120 mg	Chugai Pharmaceutical	Approved	35
Satralizumab + Placebo + Baseline Treatment	Chugai Pharmaceutical	Phase 3	40
Satralizumab + Placebo	Chugai Pharmaceutical	Phase 3	40
PDE5 Inhibitors	Eli Lilly	Pre-clinical	26
Atacicept + Placebo matched to atacicept	Merck	Phase 2	27
Fingolimod 0.5mg/daily + Placebo	Novartis	Phase 2	27
satralizumab + azathioprine (AZA) + mycophenolate mofetil (MMF) + oral corticosteroids	Roche	Phase 3	40
Satralizumab	Roche	Phase 3	47
UPLIZNA	Amgen	Pre-clinical	33
Inebilizumab	Amgen	Phase 2	42
Inebilizumab	Amgen	Approved	47
Zyvox - linezolid + Matched control	Pfizer	Phase 3	32
Dexmedetomidine HCL Injection + Placebo	Pfizer	Phase 3	40
Efgartigimod Alfa + Placebo	Argenx	Phase 2	39
Diagnostic procedures	Bayer	Approved	32
Placebo + BIIB033 100mg/Kg	Biogen	Phase 2	32
BIIB033 (anti-LINGO-1 mAb) + Placebo	Biogen	Phase 2	32
intravenous methylprednisolone	Brain Biotech	Pre-clinical	23
OCS-05 +SoC (corticosteroid) IV administration	Oculis Holding AG	Phase 2	29
EVO756 + EVO756 + EVO756 + Placebo control	Evommune	Phase 2	36